2-Butyl-4-chloro-1-(2'-(tetrazol-5-yl)biphenyl-4-ylmethyl)-1H-imidazole-5-methanol potassium

Base Information

• Chemical Name: 2-Butyl-4-chloro-1-(2'-(tetrazol-5-yl)biphenyl-4-ylmethyl)-1H-imidazole-5-methanol potassium
• CAS No.: 124750-99-8
• Molecular Formula: C22H22ClKN6OK
• Molecular Weight: 461.008
• Hs Code.: 2933290000
• European Community (EC) Number: 627-032-3,658-044-7
• NCI Thesaurus Code: C29165
• RXCUI: 203160
• Mol file: 124750-99-8.mol

Synonyms:Lorzaan;Losacor;Tenopres;Cozaar;Hyzaar;Ocsaar;Lotim;Niten;Neo Lotan;losartan potassium salt;Du Pont 753;LOSARTAN POTASSIUM;Losartan potassium [USAN];C22H23ClN6O.K;C22-H23-Cl-N6-O.K;MK 0954;124750-99-8;1H-imidazol-5-metanol, 2-butil-4-cloro-1-[[2'-(2H-tetrazol-5-il) [1,1'-bifenilo]] metil]-4-il-, potasio sal (1:1);1H-Imidazole-5-methanol 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[11'-biphenyl]-4-yl]methyl]-monopotassium salt (9CI);2-Butyl-4-chloro-1-(2'-(tetrazol-5-yl)biphenyl-4-ylmethyl)-1H-imidazole-5-methanol potassium;PD065669

Chemical Property of 2-Butyl-4-chloro-1-(2'-(tetrazol-5-yl)biphenyl-4-ylmethyl)-1H-imidazole-5-methanol potassium

Chemical Property:

• Appearance/Colour: white to off-white crystalline powder
• Vapor Pressure: 1.55E-19mmHg at 25°C
• Melting Point: ?69°C(lit.)
• Boiling Point: 682 °C at 760mmHg
• Flash Point: 366.3 °C
• PSA: 89.61000
• Density: 0.986g/mLat 25°C(lit.)
• LogP: 3.89590
• Storage Temp.: Desiccate at RT
• Solubility.: Freely soluble in water and in methanol, slightly soluble in acetonitrile.
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 6
• Rotatable Bond Count: 8
• Exact Mass: 460.1180685
• Heavy Atom Count: 31
• Complexity: 514

Purity/Quality:

99.5% ^*data from raw suppliers

Losartan potassium ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xi
• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4)CO)Cl.[K]
• Recent ClinicalTrials: Losartan for Improved Vascular Endothelial Function After Preeclampsia
• Recent EU Clinical Trials: Randomised placebo controlled clinical trial of efficacy of MYOcardial protection in patients with postacute inFLAMmatory cardiac involvEment due to COVID-19 (MYOFLAME-19)
• Description: As a angiotensin II receptor antagonist, Losartan Potassium is the potassium salt of losartan with antihypertensive activity, which is mainly used in the therapy of high blood pressure (hypertension) and diabetic nephropathy. It functions by relaxing blood vessels so that blood can flow more easily. It is also effective to help protect the kidneys from damage caused by diabetes and lower the risks of stroke in patients suffering from hypertension and myocardial enlargement. Besides, recent study has suggested that losartan is beneficial to reverse age related dysfunction in maintaining normal blood pressure and cellular energy usage on mitochondria and it can probably be used to treat left ventricular hypertrophy. It may also be used as an alternative agent for the treatment of systolic dysfunction, myocardial infarction, coronary artery disease, and heart failure. Angiotensin II is a hormone that plays an important role in regulating blood pressure. Elevated levels of angiotensin II are implicated in inducing and maintaining hypertension, and also in the development of atherosclerosis. Both of these effects are mediated by the angiotensin II type 1 (AT1) receptor. Losartan is an AT1 receptor antagonist with a Ki value of 5-20 nM. It has an attenuating effect on vein graft atherosclerosis in rabbits and effectively reduces arterial blood pressure in rats. In humans, losartan controls hypertension while protecting renal function. Losartan potassium is the first potent and selective non-peptide angiotensin II (AT II) AT1 receptor antagonist introduced to the market as a once-daily oral antihypertensive. It is efficacious and long lasting in controlling blood pressure in spontaneous hypertensive rats, in patients with essential hypertension in addition to those patients with renal impairment. Since losartan functions by competitive antagonism at the level of receptor, which represents the most direct way of selectively inhibiting the renin-angiotensin system (RAS) independent of the source of AT II, its use has been reported to be free of the coughing side effect exhibited by the ACE inhibitors. In contrast to calcium channel blockers, losartan does not appear to cause ankle edema, headache and tachycardia. It is also reported to be in clinical trials for the treatment of heart failure. Other reports indicate that losartan may have potential efficacy as an anxiolytic, an antiglaucoma agent, in addition to in providing protection against stroke and in preventing the myointimal proliferative response of the vascular wall after coronary angioplasty and surgery.
• Uses: A nonpeptide angiotensin II AT1-receptor antagonist. Antihypertensive. antihypertensive, AT1 angiotensin II antagonist Coronary vasodilator used in the diagnosis of coronary heart disease (adenosine A2A agonist).
• Therapeutic Function: Antihypertensive
• Clinical Use: #N/A
• Drug interactions: Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect. Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs. Antihypertensives: increased risk of hyperkalaemia, hypotension and renal impairment with ACE-Is and aliskiren. Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity. Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics. ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect. Lithium: reduced excretion (possibility of enhanced lithium toxicity). Potassium salts: increased risk of hyperkalaemia. Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

Technology Process of 2-Butyl-4-chloro-1-(2'-(tetrazol-5-yl)biphenyl-4-ylmethyl)-1H-imidazole-5-methanol potassium

There total 20 articles about 2-Butyl-4-chloro-1-(2'-(tetrazol-5-yl)biphenyl-4-ylmethyl)-1H-imidazole-5-methanol potassium which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 95.3%

2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole (114798-26-4) → cozaar (124750-99-8)

Guidance literature:

With potassium hydroxide; In methanol; at 40 - 45 ℃; for 0.5h; Large scale;

DOI:10.1021/op300179u

Reference yield: 95.0%

→ cozaar (124750-99-8)

Guidance literature:

Purification / work up;

Reference yield: 94.0%

lorsartan (114798-26-4) → cozaar (124750-99-8)

Guidance literature:

With potassium tert-butylate; In isopropyl alcohol; at 10 - 25 ℃; Product distribution / selectivity;

upstream raw materials:

lorsartan

2-n-Butyl-4-chloro-1-[(2'-cyanobiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde

2-n-butyl-4-chloro-1H-imidazol-5-carboxaldehyde

4'-(bromomethyl)-1,1'-biphenyl-2-carbonitrile

Downstream raw materials:

lorsartan

2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol

1-[({[(R)-5-(nitrooxy)hexyl]oxy}carbonyl)oxy]ethyl 2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate

1-[({[(R)-5-(nitrooxy)hexyl]oxy}carbonyl)oxy]ethyl 2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate

Refernces

• 1、 -. "NOVEL ZINC AZIDE COMPLEX AND A PROCESS FOR PREPARING TETRAZOLE DERIVATIVES USING THE SAME". Page/Page column 11-12. . Retrieved 2012/11/13.
• 2、 -. "A PROCESS FOR PREPARATION OF LOSARTAN POTASSIUM FORM I". Page/Page column 6. . Retrieved 2010/05/13.